News Search Results
Nov 13, 2025, 08:00 ET Cohen & Steers Promotes Daniel Noonan to Head of Global Distribution
NEW YORK, Nov. 13, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that Daniel Noonan, Executive Vice President and Head of Global Wealth, has been promoted to Head of Global Distribution. Mr. Noonan
More news about: Cohen & Steers, Inc.
Nov 13, 2025, 08:00 ET LISCure Expands Global Partnerships for BBB Shuttle Platform 'ExoPN-101'; Signs Fourth MTA with Leading Pharma Partner
therapeutics through advanced platform innovation. The company's pipeline includes ExoPN-101, a proprietary BBB shuttle platform for central nervous system (CNS) drug delivery, and LB-P8, a Phase 2 therapeutic candidate for Primary Sclerosing Cholangitis (PSC). LISCure aims to advance cutting-edge science into
More news about: LISCure BioSciences
Nov 12, 2025, 08:30 ET Corundum Neuroscience Invests in NextSense to Support Commercialization of Smartbuds
Corundum Neuroscience (CNS), the neuroscience venture builder and fund announced today they have participated in a Series A funding round for
More news about: Corundum Neuroscience
Nov 11, 2025, 07:45 ET Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
preclinical research evaluating Modeyso™ (dordaviprone), as well as new preclinical data featuring JZP3507 (formerly ONC206) in central nervous system (CNS) tumors, reflecting Jazz's growing impact and innovation in neuro-oncology. Key presentations include:
More news about: Jazz Pharmaceuticals plc
Nov 10, 2025, 16:22 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for October 2025
NEW YORK, Nov. 10, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $90.6 billion as of October 31, 2025, a decrease of $312 million from assets under management
More news about: Cohen & Steers, Inc.
Nov 10, 2025, 09:00 ET NEURELIS TO PARTICIPATE IN SOFIE'S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT
narrow-angle glaucoma Central Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Nov 10, 2025, 08:00 ET Servier's Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma
Astrocytoma, IDH-mutant (CNS WHO grades 2-4) Oligodendroglioma, IDH-mutant and1p19q-codeleted (CNS WHO grades 2-3) Glioblastoma, IDH-wildtype (CNS WHO grade 4)
More news about: Servier Pharmaceuticals
Nov 07, 2025, 08:58 ET Resonant Wins BioTech Breakthrough Awards' "DNA Sequencing Innovation Of The Year"
Resonant turns next-generation sequencing into a practical, blood-based view of active CNS injury, revealing meaningful biology when intervention has the greatest chance of success. A simple blood draw delivers a scalable, CNS-resolved measure of active neurodegeneration that sets a new standard for how sequencing
More news about: Resonant
Nov 06, 2025, 16:00 ET Curis Provides Third Quarter 2025 Business Update
NHL/CLL Curis will report clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19-23:
More news about: Curis, Inc.
Nov 06, 2025, 12:12 ET A Corero Network Security aproveita os resultados do terceiro trimestre com grandes conquistas no quarto trimestre e avanços em seus produtos
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), líder reconhecida em proteção contra DDoS e campeã de disponibilidade de serviços adaptáveis e em tempo real, relatou hoje uma aceleração
More news about: Corero Network Security
Nov 06, 2025, 12:10 ET Corero Network Security se apoya en la ejecución del tercer trimestre con importantes logros y avances de productos en el cuarto trimestre
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), líder reconocida en protección contra ataques distribuidos de denegación de servicio (DDoS, por sus siglas en inglés) y defensora de
More news about: Corero Network Security
Nov 06, 2025, 09:00 ET NEURELIS TO PRESENT STUDY OF NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT SYMPTOMATIC CEREBRAL CAVERNOUS MALFORMATIONS (CCM), AT ANNUAL CCM MEETING
narrow-angle glaucoma Central Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Nov 06, 2025, 07:00 ET NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
expected impact of his expertise on the Company's research and development programs, and the potential advancement of NewcelX's combined cell therapy and CNS drug development platforms following the merger of Kadimastem and NLS Pharmaceutics and its ability to deliver meaningful therapeutic advances for patients
More news about: NewcelX Ltd.
Nov 05, 2025, 12:01 ET Connected Nation curates AI training and literacy resources to ensure new learners are skilled for the future
Empower AI Learners: Train at least 50,000 K–12 students in AI literacy and application skills through CN's national digital empowerment programs, with a focus on rural and underserved communities. Advance
More news about: Connected Nation
Nov 05, 2025, 08:34 ET CNS Summit releases annual Digital Innovation Index
BOSTON, Nov. 5, 2025 /PRNewswire/ -- The CNS Summit Digital Innovation Index, created in partnership with IDEA Pharma, a division of SAI Med Partners, was unveiled during the CNS Summit annual meeting on November 4. The Index continues to assess and rank biopharma
More news about: CNS Summit
Nov 05, 2025, 03:00 ET Corero Network Security Builds on Q3 Execution with Major Q4 Wins and Product Breakthroughs
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today reported accelerating global
More news about: Corero Network Security
Nov 05, 2025, 03:00 ET Corero Network Security Builds on Q3 Execution with Major Q4 Wins and Product Breakthroughs
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today reported accelerating global
More news about: Corero Network Security
Nov 04, 2025, 17:12 ET Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Nov 04, 2025, 16:01 ET Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
ocadusertib. In early October, Rigel received notification from Lilly that it will terminate the central nervous system (CNS) disease program related to the collaboration between the two companies, which will become effective 60 days following notification.
More news about: Rigel Pharmaceuticals, Inc.
Nov 04, 2025, 07:00 ET NewcelX CEO Issues Letter to Shareholders
neurodegenerative diseases. The DOXA program gives NewcelX a pipeline engine with the potential to generate multiple assets across Central Nervous System (CNS) and metabolic disorders. The scientific horizon here is wide, and the commercial opportunities reach large, underserved populations.
More news about: NewcelX Ltd.
Nov 03, 2025, 19:00 ET Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases
barrier. Through this platform, the company is developing multiple therapeutic candidates aimed at addressing the significant unmet clinical needs in CNS autoimmune diseases, an area that remains largely unexplored. Founded in 2022, Kaigene is currently in the Pre-A bridging investment stage and has raised
More news about: Kaigene
Nov 03, 2025, 17:31 ET Chronic Progressive Multiple Sclerosis Market to Witness Accelerated Expansion During the Forecast Period (2025-2034) Due to Strong Pipeline and Advanced Therapeutic Strategies | DelveInsight
Tolebrutinib is an investigational oral BTK inhibitor specifically developed to cross the blood–brain barrier and remain active within the central nervous system (CNS). Its goal is to target smoldering neuroinflammation, a key driver of disability progression in multiple sclerosis. In contrast to conventional multiple
More news about: DelveInsight Business Research, LLP
Nov 03, 2025, 14:23 ET Vascarta Inc: Transdermal Curcumin (VAS-101 Drug Candidate) Interrupts the Neuroinflammatory Pathophysiological Cascade Associated with Acute Sickle Cell Crisis
mitochondrial membrane potential. The investigators conclude that IL-17 orchestrates acute pain by promoting the IL-17-TNF-α/IL-6–p38 cascade in the CNS and periphery, leading to oxidative stress and mitochondrial dysfunction in sensory neurons. VAS-101 interrupts this SCD pathophysiological cascade,
More news about: Vascarta Inc
Nov 03, 2025, 08:08 ET Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimus–treated patients, including 1 fatal cerebral hemorrhage.
More news about: Eisai Inc.
Nov 03, 2025, 08:00 ET Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
Astrocytoma, IDH-mutant (CNS WHO grades 2-4) Oligodendroglioma, IDH-mutant and1p19q-codeleted (CNS WHO grades 2-3) Glioblastoma, IDH-wildtype (CNS WHO grade 4)
More news about: Servier Pharmaceuticals